TNGXTango Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+8.2% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$33M-283.3% margin

Net Income

-$29M-251.3% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-41.6%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$34M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$352M

Total Liabilities

$123M

Stockholders' Equity

$229M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$11M	+8.2%
Gross Profit	$12M	$10M	+14.7%
Operating Income	-$33M	-$26M	-28.3%
Net Income	-$29M	-$22M	-31.0%

Revenue Segments

License Revenue

$12M51%

Collaboration Revenue

$12M49%

TNGX Q3 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena